Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple Myeloma

ID#: NCT03858205

Age: 18 years - 66+

Gender: All

Healthy Subjects: No

Study Phase: N/A

Recruitment Status: Recruiting

Start Date: March 11, 2019

End Date: March 11, 2022

Contact Information:
Christine Duran
323-865-0371
Summary: This phase II trial studies how well low-dose radiotherapy works in treating bone pain in patients with multiple myeloma that has spread to the bone. Radiation therapy uses high energy x-rays, gamma rays, neutrons, protons, or other sources to kill tumor cells and shrink tumors. Low-dose radiotherapy may be more convenient for patients and their families, may not interfere as much with the timing of chemotherapy, and may have less chance for short term or long-term side effects from the radiation.
Eligibility:

Inclusion Criteria:

- Histologic diagnosis of multiple myeloma

- Painful bone metastasis (index lesion) that has a radiographic correlate

- Patient may have had any number of prior chemotherapy/immunotherapy regimens (changes to systemic therapy or use of bisphosphonates for 4 weeks before and after RT are allowed, but recording of these changes must be made so it can be accounted for)

- Eastern Cooperative Oncology Group (ECOG) 0-2

- Brief Pain Inventory (BPI) score >= 2

- Ability to understand and the willingness to sign a written informed consent

Exclusion Criteria:

- Patients will be ineligible if the index lesion has received prior radiation therapy or prior palliative surgery. Patients may have received prior palliative or primary radiotherapy or surgery to other parts of the body, as long as the index lesion was not in the prior radiation fields and has not received prior palliative surgery

- Patients will also be ineligible if there is pathologic fracture or impending fracture at the site of the index lesion or planned surgical fixation of the bone at the index lesion

- Patients with clinical or radiographic evidence of spinal cord or cauda equina compression/effacement from the index lesion, and/or with index lesions located at the skull base or orbital lesions

- Patients must not be pregnant